

Dominique Roulot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7624796/publications.pdf>

Version: 2024-02-01

113
papers

7,327
citations

57758

44
h-index

54911

84
g-index

116
all docs

116
docs citations

116
times ranked

6997
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-invasive diagnosis and follow-up of chronic infection with hepatitis B virus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101773.	1.5	2
2	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	7.3	107
3	ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. <i>Liver International</i> , 2022, 42, 1386-1400.	3.9	2
4	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	4.4	80
5	Bulevirtide with or without pegIFN± for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. <i>Journal of Hepatology</i> , 2022, 77, 1422-1430.	3.7	54
6	Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	2.7	12
7	Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. <i>Digestive Diseases and Sciences</i> , 2021, 66, 881-898.	2.3	3
8	Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype. <i>Viruses</i> , 2021, 13, 1572.	3.3	9
9	Comprehensive Analysis of Hepatitis Delta Virus Assembly Determinants According to Genotypes: Lessons From a Study of 526 Hepatitis Delta Virus Clinical Strains. <i>Frontiers in Microbiology</i> , 2021, 12, 751531.	3.5	4
10	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	3.7	52
11	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	3.7	79
12	Screening for Liver Fibrosis in General or At-Risk Populations Using Transient Elastography. , 2020, , 545-550.		1
13	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	3.7	104
14	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. <i>Gastroenterology</i> , 2019, 156, 997-1009.e5.	1.3	100
15	Non-virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	2.0	16
16	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	7.3	33
17	Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 302-309.	1.6	2
18	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	2.7	49

#	ARTICLE	IF	CITATIONS
19	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	1.3	183
20	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	1.3	81
21	Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 1274-1283.	3.7	86
22	Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study. <i>Nutrients</i> , 2018, 10, 60.	4.1	8
23	Molecular diversity of HBV and HDV amino-acid sequences involved in HDV virion morphogenesis according to HBV and HDV genotypes: study of 1590 clinical strains. <i>Journal of Hepatology</i> , 2018, 68, S783-S784.	3.7	1
24	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 T	12.1	59
25	Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan. <i>Liver International</i> , 2017, 37, 1897-1906.	3.9	68
26	Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. <i>Hepatology</i> , 2017, 66, 1826-1841.	7.3	94
27	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. <i>Journal of Hepatology</i> , 2017, 67, 1334-1339.	3.7	32
28	Performance Characteristics of a New Consensus Commercial Kit for Hepatitis D Virus RNA Viral Load Quantification. <i>Journal of Clinical Microbiology</i> , 2017, 55, 431-441.	3.9	37
29	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. <i>Gastroenterology</i> , 2017, 152, 142-156.e2.	1.3	420
30	Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort). <i>Journal of Hepatology</i> , 2016, 64, S273.	3.7	0
31	New Recommendations of Baveno VI Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S178.	3.7	3
32	The Benefits of Viro-suppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S655-S656.	3.7	0
33	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	7.3	75
34	Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort). <i>Journal of Hepatology</i> , 2016, 64, S194-S195.	3.7	2
35	Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies. <i>Liver International</i> , 2016, 36, 1059-1066.	3.9	35
36	Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection. <i>Blood</i> , 2016, 128, 4898-4898.	1.4	0

#	ARTICLE	IF	CITATIONS
37	P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12) Tj ETQq1 1 0.384314 rgBT /Overlock 10 Tf 50 70	3.7	6
38	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	7.3	96
39	G08 : Incidence of hepatocellular carcinoma (HCC) and complications in alcoholic compensated cirrhosis. Preliminary results of a multicenter prospective French and belgian cohort (INCA Cirral). Journal of Hepatology, 2015, 62, S213-S214.	3.7	6
40	P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France. Journal of Hepatology, 2015, 62, S532-S533.	3.7	1
41	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. Journal of Hepatology, 2015, 62, S541-S542.	3.7	5
42	Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology, 2015, 61, 660-667.	7.3	364
43	High Frequency of X Chromosome Abnormalities in Women With Short Stature and Elevated Liver Enzymes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1592-E1596.	3.6	1
44	Serological and Molecular Diagnosis of Hepatitis Delta Virus Infection: Results of a French National Quality Control Study. Journal of Clinical Microbiology, 2014, 52, 1694-1697.	3.9	24
45	112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS) Tj ETQq1 1 0.7843	3.7	6
46	Liver involvement in Turner syndrome. Liver International, 2013, 33, 24-30.	3.9	68
47	Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases. European Journal of Gastroenterology and Hepatology, 2013, 25, 94-98.	1.6	16
48	Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis. Cancer Prevention Research, 2012, 5, 1007-1014.	1.5	66
49	Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: A new strategy?. Journal of Hepatology, 2012, 56, 14-16.	3.7	7
50	1254 RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS E: A CASE-SERIES. Journal of Hepatology, 2011, 54, S495.	3.7	5
51	Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut, 2011, 60, 977-984.	12.1	272
52	643 IMPROVED EFFICIENCY OF HCC SCREENING IS MAINLY DUE TO THE INTRODUCTION OF RFA AS THE FIRST LINE CURATIVE TREATMENT. Journal of Hepatology, 2011, 54, S260.	3.7	0
53	Prevalence and Clinical Significance of KÄ¼pffer Cell Hyperplasia With Hemophagocytosis in Liver Biopsies. American Journal of Surgical Pathology, 2011, 35, 337-345.	3.7	26
54	Liver stiffness diminishes with antiviral response in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2011, 34, 656-663.	3.7	113

#	ARTICLE	IF	CITATIONS
55	HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. <i>Journal of Viral Hepatitis</i> , 2011, 18, e516-e522.	2.0	152
56	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. <i>Hepatology</i> , 2011, 54, 1987-1997.	7.3	309
57	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011, 11, 496-503.	2.3	14
58	Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 827-833.	3.7	96
59	Turner syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before and during pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 152, 18-24.	1.1	96
60	401 LIVER STIFFNESS DYNAMICS IN HCV-INFECTED PATIENTS WITH AND WITHOUT AN SVR TO PEGINTERFERON ALPHA-RIBAVIRIN TREATMENT. FINAL RESULTS OF A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2010, 52, S164.	3.7	0
61	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	5.0	56
62	219 LIVER STIFFNESS MEASUREMENT: AN APPROPRIATE SCREENING METHOD TO DETECT LIVER FIBROSIS IN THE GENERAL POPULATION. <i>Journal of Hepatology</i> , 2009, 50, S89.	3.7	2
63	615 PROSPECTIVE EVALUATION OF LIVER STIFFNESS DYNAMICS DURING AND AFTER PEGINTERFERON ALPHA-RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2009, 50, S226.	3.7	3
64	Applicability and variability of liver stiffness measurements according to probe position. <i>World Journal of Gastroenterology</i> , 2009, 15, 3398.	3.3	19
65	Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. <i>Journal of Hepatology</i> , 2008, 48, 606-613.	3.7	372
66	446 REDUCED HEPATIC EXPRESSION OF PERFORIN AND GRANZYME B IN PATIENTS WITH HEMOPHAGOCYTIC SYNDROME. <i>Journal of Hepatology</i> , 2008, 48, S170.	3.7	0
67	793 DYNAMICS OF LIVER STIFFNESS DURING PEGINTERFERON ALPHA-RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2008, 48, S296.	3.7	2
68	965 IS LIVER STIFFNESS MEASUREMENT AN APPROPRIATE SCREENING METHOD TO DETECT LIVER FIBROSIS IN THE GENERAL POPULATION?. <i>Journal of Hepatology</i> , 2008, 48, S361.	3.7	8
69	Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers. <i>PLoS ONE</i> , 2008, 3, e3857.	2.5	75
70	[597] EVOLUTION OF LIVER STIFFNESS MEASUREMENT DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2007, 46, S226.	3.7	0
71	Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus-Related Cirrhosis: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 502-507.	4.4	45
72	Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 460-467.	2.0	105

#	ARTICLE	IF	CITATIONS
73	Risks factors of liver fibrosis in a cohort of intravenous drug users coinfectd with HIV and HCV at the HAART era: the role of mixed steatosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 822-827.	0.9	4
74	550 Progression and severity of liver fibrosis in HIV-HCV co-infected patients with normal CD4 cell count: Comparison with HCV-infected patients. <i>Journal of Hepatology</i> , 2006, 44, S205.	3.7	1
75	649 high frequency of X chromosome abnormalities in short stature women with unexplained elevated liver enzymes. <i>Journal of Hepatology</i> , 2006, 44, S240-S241.	3.7	0
76	Hepatic disease in Turner syndrome. <i>International Congress Series</i> , 2006, 1298, 146-151.	0.2	4
77	Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis - ANRS HC EP07 study*. <i>Journal of Viral Hepatitis</i> , 2006, 13, 474-481.	2.0	15
78	Rheumatologic manifestations of chronic hepatitis C infection. <i>Joint Bone Spine</i> , 2006, 73, 633-638.	1.6	74
79	Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 175-179.	2.1	323
80	Severe streptococcal cellulitis after subcutaneous pegylated interferon alfa-2B in a diabetic patient. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 1294-1295.	0.9	4
81	Vascular involvement of the liver in Turner's syndrome. <i>Hepatology</i> , 2004, 39, 239-247.	7.3	110
82	Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. <i>Hepatology</i> , 2004, 40, 1361-1369.	7.3	93
83	Molecular Phylogenetic Analyses Indicate a Wide and Ancient Radiation of African Hepatitis Delta Virus, Suggesting a <i>Deltavirus</i> Genus of at Least Seven Major Clades. <i>Journal of Virology</i> , 2004, 78, 2537-2544.	3.4	215
84	367 Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus suggesting a deltavirus genus to be composed of at least seven major clades. <i>Journal of Hepatology</i> , 2004, 40, 110.	3.7	1
85	A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. <i>Hepatology</i> , 2003, 37, 887-892.	7.3	30
86	HCV infection screening and treatment in drug users followed in an addiction out patient unit. <i>Journal of Hepatology</i> , 2002, 36, 109.	3.7	0
87	Liver involvement in turner syndrome. <i>Journal of Hepatology</i> , 2002, 36, 160.	3.7	1
88	Transforming growth factor β^2 and the liver. <i>Hepatology</i> , 2001, 34, 859-867.	7.3	307
89	Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. <i>Journal of General Virology</i> , 2001, 82, 1001-1012.	2.9	91
90	<i>In vivo</i> inhibition of rat stellate cell activation by soluble transforming growth factor β^2 type II receptor: A potential new therapy for hepatic fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 12719-12724.	7.1	318

#	ARTICLE	IF	CITATIONS
91	Role of transforming growth factor β type II receptor in hepatic fibrosis: Studies of human chronic hepatitis C and experimental fibrosis in rats. <i>Hepatology</i> , 1999, 29, 1730-1738.	7.3	107
92	Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. <i>Journal of Hepatology</i> , 1998, 29, 430-436.	3.7	192
93	Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 5-10.	1.6	63
94	Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. <i>Journal of Hepatology</i> , 1996, 25, 135-144.	3.7	425
95	Quantitative analysis of transforming growth factor β 1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease. <i>Hepatology</i> , 1995, 21, 298-304.	7.3	50
96	Successful treatment by mesocaval anastomosis of a common-bile-duct compression by choledochal varices. <i>Journal of Hepatology</i> , 1995, 23, 629-630.	3.7	7
97	Quantitative analysis of transforming growth factor β 1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease*1. <i>Hepatology</i> , 1995, 21, 298-304.	7.3	3
98	Renal Hemodynamics in Patients with Cirrhosis: Relationship with Ascites and Liver Failure. <i>Nephron</i> , 1993, 65, 359-363.	1.8	22
99	Identification of the <i>Rochalimaea henselae</i> 16S rRNA Sequence in the Liver of a French Patient with Bacillary Peliosis Hepatis. <i>Journal of Infectious Diseases</i> , 1992, 166, 1462-1463.	4.0	25
100	Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1992, 102, 1309-1318.	1.3	42
101	Low rate of hepatitis C virus (HCV) transmission within the family. <i>Journal of Hepatology</i> , 1992, 14, 409-410.	3.7	8
102	Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: A multicenter sequential trial. <i>Hepatology</i> , 1992, 15, 76-81.	7.3	78
103	Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. <i>Hepatology</i> , 1991, 14, 483-487.	7.3	1
104	Hemodynamic effects of dopamine in conscious rats with secondary biliary cirrhosis. <i>Journal of Hepatology</i> , 1990, 11, 257-262.	3.7	1
105	Hemodynamic effects of a combination of clonidine and propranolol in conscious cirrhotic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 1989, 67, 1369-1372.	1.4	25
106	Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: Evidence for an impaired cardiopulmonary baroreflex function. <i>Hepatology</i> , 1989, 10, 93-97.	7.3	33
107	Hepatic denervation alters hemodynamic response to hemorrhage in conscious rats. <i>Hepatology</i> , 1989, 10, 473-476.	7.3	19
108	Mechanisms of a clonidine-induced decrease in portal pressure in normal and cirrhotic conscious rats. <i>Hepatology</i> , 1989, 10, 477-481.	7.3	26

#	ARTICLE	IF	CITATIONS
109	Hyperkinetic circulatory syndrome in patients with presinusoidal portal hypertension. <i>Journal of Hepatology</i> , 1989, 9, 312-318.	3.7	46
110	Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. <i>Journal of Hepatology</i> , 1989, 9, 246-251.	3.7	32
111	Effects of oxygen inhalation on tissue oxygenation in patients with cirrhosis. <i>Journal of Hepatology</i> , 1989, 9, 240-245.	3.7	23
112	Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis. <i>Journal of Hepatology</i> , 1988, 7, 118-125.	3.7	138
113	Cholangitis in the acquired immunodeficiency syndrome: report of two cases and review of the literature.. <i>Gut</i> , 1987, 28, 1653-1660.	12.1	33